MITF and melanoma: In a study on xenograft models to stimulate awakening in dormant cells, thus making them more susceptible to treatment, methotrexate was reported to favor the phenotypic switch from a MITF low to an MITF high state, thus sensitizing melanoma cells to a tyrosinase-processed antifolate prodrug [94].